<DOC>
	<DOCNO>NCT01062503</DOCNO>
	<brief_summary>Bone common site metastasis prostate cancer bone complication cause substantial morbidity population . Phase III study show zoledronic acid effective decrease morbidity associate bone metastasis . Zoledronic acid ( ZA ) generally well tolerate may side effect hypocalcemia , renal impairment osteonecrosis jaw . Administration ZA infrequently yearly sufficient prevent osteopenia osteoporosis . The optimal treatment interval unknown , drug often empirically administer every 3-4 week . The cost treatment high , risk expose patient ( especially low risk ) potential serious side effect uncertain benefit warrant investigation . This study determine duration suppression bone turnover prostate cancer patient bone metastasis follow single infusion Zoledronic Acid effect quality life .</brief_summary>
	<brief_title>Duration Suppression Bone Turnover Following Treatment With Zoledronic Acid Men With Metastatic CRPC</brief_title>
	<detailed_description>The bone common site metastasis men prostate cancer , bone metastasis associate significant risk SREs . Prevention delay onset SREs demonstrate use ZA . The optimal dosing frequency ZA know population usually give every 3-4 week , whereas injection infrequently yearly protect bone loss patient without bone metastasis receive ADT . uNTX , sCTX BAP marker bone turnover bone formation suppress response ZA associate likelihood development SRE . In study , propose determine duration suppression bone turnover ( uNTX , sCTX BAP ) response single dose ZA patient castration resistant prostate cancer metastatic bone . Our objective study : 1 . To estimate proportion patient suppression bone turnover 12 week administration single dose ZA . 2 . To estimate distribution duration suppression bone turnover 12 week administration ZA . 3 . To evaluate frequency SREs experience patient population . 4 . To measure quality life presence bone pain 12 week period patient population utilize Functional Assessment Cancer Therapy - Bone Pain ( FACT-BP ) Brief Pain Inventory ( BPI ) questionnaires .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients must histologically confirm prostate cancer become castration resistant Radiological pathological evidence bone metastasis . ( Positive bone scan , MRI , CT pathological fracture , pathological sample bone biopsy show evidence metastatic prostate cancer ) Patient yet start BP therapy metastatic castration resistant prostate cancer Renal hepatic function within institutional normal range discretion Investigator Age ≥ 18 year ECOG performance status ≤ 2 Life expectancy &gt; 6 month Ability understand willingness sign write informed consent document Hypersensitivity know allergy bisphosphonates Patient receive BP therapy reason within past 1 year Acute chronic renal insufficiency Evidence infection/abscess dental exam recent dental extraction ( within last 4 week ) Acute pathological fracture , spinal cord compression , hypercalcemia require urgent treatment ( patient may enter study acute issue resolve ) Patients baseline hypocalcemia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Prostate</keyword>
	<keyword>metastatic</keyword>
</DOC>